Utah Medical Products Inc
UTMD Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2016–FY2025
Last close · Oct 23, 2026
$74.23
1.1%
Revenue
Total sales reported in the income statement.
$38.5M
5.8%
vs prior year
Operating margin
Operating income as a share of revenue.
29.6%
3.6 pts
Net income
Profit after all expenses, interest and tax.
$11.3M
18.7%
Free cash flow
Cash from operations minus capital spending.
$14.3M
1.9%
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
27.2%
5.4 pts
Market cap
Last close times the latest diluted share count, so it is approximate.
$236M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
22.6x
On $3.28 EPS (TTM)
What Utah Medical Products Inc does
No business description yet.
- Legal name
- UTAH MEDICAL PRODUCTS INC
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 27, 2026
- Accession · CIK
- 0001096906-26-000395
0000706698
Revenue and margins
Utah Medical Products Inc had $38.5M of revenue in fiscal 2025, down 5.8% on the year before.
FY16
Revenue $39.3M
FY17
Revenue $41.4M
FY18
Revenue $42.0M
FY19
Revenue $46.9M
FY20
Revenue $42.2M
FY21
Revenue $49.1M
FY22
Revenue $52.3M
FY23
Revenue $50.2M
FY24
Revenue $40.9M
FY25
Revenue $38.5M
Q3 '23
Revenue $12.5M
Q4 '23
Revenue $12.3M
Q1 '24
Revenue $11.3M
Q2 '24
Revenue $10.4M
Q3 '24
Revenue $10.0M
Q4 '24
Revenue $9.2M
Q1 '25
Revenue $9.7M
Q2 '25
Revenue $10.0M
Q3 '25
Revenue $9.8M
Q4 '25
Revenue $9.0M
Q1 '26
Revenue $8.7M
Q2 '26
Revenue $8.5M
FY16
Gross 60.3%
Operating 41.2%
Net 30.9%
FCF 28.6%
FY17
Gross 63.7%
Operating 45.9%
Net 20.5%
FCF 37.0%
FY18
Gross 62.6%
Operating 44.5%
Net 44.2%
FCF 39.1%
FY19
Gross 62.8%
Operating 37.6%
Net 31.4%
FCF 35.2%
FY20
Gross 60.6%
Operating 32.5%
Net 25.6%
FCF 45.7%
FY21
Gross 63.0%
Operating 38.5%
Net 30.1%
FCF 42.1%
FY22
Gross 61.6%
Operating 37.9%
Net 31.5%
FCF 38.9%
FY23
Gross 59.8%
Operating 33.4%
Net 33.1%
FCF 43.1%
FY24
Gross 59.0%
Operating 33.2%
Net 33.9%
FCF 35.7%
FY25
Gross 57.1%
Operating 29.6%
Net 29.3%
FCF 37.2%
Gross
Operating
Net
FCF
Q3 '23
Gross 58.8%
Operating 31.7%
Net 31.5%
FCF 39.5%
Q4 '23
Gross 57.6%
Operating 32.0%
Net 34.8%
FCF 42.5%
Q1 '24
Gross 59.7%
Operating 34.2%
Net 34.9%
FCF 46.3%
Q2 '24
Gross 60.1%
Operating 33.1%
Net 33.2%
FCF 25.5%
Q3 '24
Gross 58.0%
Operating 33.4%
Net 35.6%
FCF 37.7%
Q4 '24
Gross 58.1%
Operating 32.0%
Net 31.7%
FCF 32.0%
Q1 '25
Gross 57.0%
Operating 32.5%
Net 31.3%
FCF 44.1%
Q2 '25
Gross 56.2%
Operating 32.1%
Net 30.6%
FCF 28.4%
Q3 '25
Gross 57.1%
Operating 26.6%
Net 26.8%
FCF 39.2%
Q4 '25
Gross 58.2%
Operating 27.0%
Net 28.4%
FCF 37.2%
Q1 '26
Gross 60.6%
Operating 29.4%
Net 29.9%
FCF 34.2%
Q2 '26
Gross 55.8%
Operating 31.1%
Net 31.5%
FCF 14.6%
Gross
Operating
Net
FCF
Net income and earnings per share
From fiscal 2016 to 2025, diluted EPS grew 0.9% a year. Loss periods are shown in red.
FY16
Net income $12.1M
FY17
Net income $8.5M
FY18
Net income $18.6M
FY19
Net income $14.7M
FY20
Net income $10.8M
FY21
Net income $14.8M
FY22
Net income $16.5M
FY23
Net income $16.6M
FY24
Net income $13.9M
FY25
Net income $11.3M
Q3 '23
Net income $3.9M
Q4 '23
Net income $4.3M
Q1 '24
Net income $4.0M
Q2 '24
Net income $3.5M
Q3 '24
Net income $3.6M
Q4 '24
Net income $2.9M
Q1 '25
Net income $3.0M
Q2 '25
Net income $3.0M
Q3 '25
Net income $2.6M
Q4 '25
Net income $2.6M
Q1 '26
Net income $2.6M
Q2 '26
Net income $2.7M
FY16
Diluted EPS $3.22
FY17
Diluted EPS $2.28
FY18
Diluted EPS $4.95
FY19
Diluted EPS $3.94
FY20
Diluted EPS $2.94
FY21
Diluted EPS $4.04
FY22
Diluted EPS $4.52
FY23
Diluted EPS $4.57
FY24
Diluted EPS $3.96
FY25
Diluted EPS $3.48
Q3 '23
Diluted EPS $1.08
Q4 '23
Diluted EPS $1.18
Q1 '24
Diluted EPS $1.09
Q2 '24
Diluted EPS $0.98
Q3 '24
Diluted EPS $1.03
Q4 '24
Diluted EPS $0.86
Q1 '25
Diluted EPS $0.92
Q2 '25
Diluted EPS $0.94
Q3 '25
Diluted EPS $0.82
Q4 '25
Diluted EPS $0.80
Q1 '26
Diluted EPS $0.82
Q2 '26
Diluted EPS $0.84
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY16
Return on capital —
Return on equity 17.5%
Return on assets 15.9%
FY17
Return on capital 32.3%
Return on equity 11.5%
Return on assets 10.1%
FY18
Return on capital 47.1%
Return on equity 22.2%
Return on assets 19.3%
FY19
Return on capital 24.9%
Return on equity 15.5%
Return on assets 14.1%
FY20
Return on capital 20.9%
Return on equity 10.6%
Return on assets 9.7%
FY21
Return on capital 31.7%
Return on equity 14.1%
Return on assets 13.0%
FY22
Return on capital 40.3%
Return on equity 14.9%
Return on assets 13.8%
FY23
Return on capital 39.2%
Return on equity 13.7%
Return on assets 12.8%
FY24
Return on capital 32.6%
Return on equity 11.3%
Return on assets 10.8%
FY25
Return on capital 27.2%
Return on equity 9.5%
Return on assets 9.2%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was $14.3M in fiscal 2025, 37.2% of revenue. Cash from operations minus capital spending.
FY16
Free cash flow $11.2M
FY17
Free cash flow $15.3M
FY18
Free cash flow $16.4M
FY19
Free cash flow $16.5M
FY20
Free cash flow $19.3M
FY21
Free cash flow $20.7M
FY22
Free cash flow $20.3M
FY23
Free cash flow $21.6M
FY24
Free cash flow $14.6M
FY25
Free cash flow $14.3M
Q3 '23
Free cash flow $4.9M
Q4 '23
Free cash flow $5.2M
Q1 '24
Free cash flow $5.3M
Q2 '24
Free cash flow $2.7M
Q3 '24
Free cash flow $3.8M
Q4 '24
Free cash flow $2.9M
Q1 '25
Free cash flow $4.3M
Q2 '25
Free cash flow $2.8M
Q3 '25
Free cash flow $3.9M
Q4 '25
Free cash flow $3.4M
Q1 '26
Free cash flow $3.0M
Q2 '26
Free cash flow $1.2M
FY16
Cash from operations $14.5M
Capital spending $3.3M
FY17
Cash from operations $16.9M
Capital spending $1.6M
FY18
Cash from operations $16.8M
Capital spending $0.4M
FY19
Cash from operations $17.1M
Capital spending $0.5M
FY20
Cash from operations $20.1M
Capital spending $0.9M
FY21
Cash from operations $21.2M
Capital spending $0.6M
FY22
Cash from operations $21.1M
Capital spending $0.8M
FY23
Cash from operations $22.3M
Capital spending $0.6M
FY24
Cash from operations $14.8M
Capital spending $0.2M
FY25
Cash from operations $14.7M
Capital spending $0.4M
Cash from operations
Capital spending
Q3 '23
Cash from operations $5.1M
Capital spending $0.2M
Q4 '23
Cash from operations $5.3M
Capital spending $0.1M
Q1 '24
Cash from operations $5.3M
Capital spending $0.0M
Q2 '24
Cash from operations $2.8M
Capital spending $0.1M
Q3 '24
Cash from operations $3.9M
Capital spending $0.1M
Q4 '24
Cash from operations $2.9M
Capital spending $0.0M
Q1 '25
Cash from operations $4.5M
Capital spending $0.2M
Q2 '25
Cash from operations $2.9M
Capital spending $0.1M
Q3 '25
Cash from operations $3.9M
Capital spending $0.0M
Q4 '25
Cash from operations $3.5M
Capital spending $0.1M
Q1 '26
Cash from operations $3.1M
Capital spending $0.1M
Q2 '26
Cash from operations $1.4M
Capital spending $0.1M
Cash from operations
Capital spending
Dividends, buybacks and share count
Utah Medical Products Inc returned $12.3M to shareholders in fiscal 2025, 86% of free cash flow. The diluted share count fell 7.5%.
FY16
Dividends $3.9M
Buybacks —
FY17
Dividends $3.0M
Buybacks $0.0M
FY18
Dividends $4.0M
Buybacks $1.2M
FY19
Dividends $4.1M
Buybacks $0.4M
FY20
Dividends $4.1M
Buybacks $7.0M
FY21
Dividends $11.5M
Buybacks $0.0M
FY22
Dividends $3.2M
Buybacks $2.5M
FY23
Dividends $4.3M
Buybacks $0.0M
FY24
Dividends $4.3M
Buybacks $20.0M
FY25
Dividends $4.0M
Buybacks $8.4M
Dividends
Buybacks
Q3 '23
Dividends $1.1M
Buybacks $0.0M
Q4 '23
Dividends $1.1M
Buybacks $0.0M
Q1 '24
Dividends $1.1M
Buybacks $3.0M
Q2 '24
Dividends $1.1M
Buybacks $6.4M
Q3 '24
Dividends $1.1M
Buybacks $3.9M
Q4 '24
Dividends $1.0M
Buybacks $6.7M
Q1 '25
Dividends $1.0M
Buybacks $3.2M
Q2 '25
Dividends $1.0M
Buybacks $3.5M
Q3 '25
Dividends $1.0M
Buybacks $0.7M
Q4 '25
Dividends $1.0M
Buybacks $1.0M
Q1 '26
Dividends $1.0M
Buybacks $0.1M
Q2 '26
Dividends $1.0M
Buybacks $0.1M
Dividends
Buybacks
FY16
Diluted shares 0.00B
FY17
Diluted shares 0.00B
FY18
Diluted shares 0.00B
FY19
Diluted shares 0.00B
FY20
Diluted shares 0.00B
FY21
Diluted shares 0.00B
FY22
Diluted shares 0.00B
FY23
Diluted shares 0.00B
FY24
Diluted shares 0.00B
FY25
Diluted shares 0.00B
Balance sheet
Cash, debt and the ratios that show how comfortably Utah Medical Products Inc can carry it.
FY16
Cash $26.3M
Debt —
FY17
Cash $39.9M
Debt $0.0M
FY18
Cash $51.1M
Debt $0.0M
FY19
Cash $42.8M
Debt $0.0M
FY20
Cash $51.6M
Debt $0.0M
FY21
Cash $61.0M
Debt $0.0M
FY22
Cash $75.1M
Debt $0.0M
FY23
Cash $92.9M
Debt $0.0M
FY24
Cash $83.0M
Debt $0.0M
FY25
Cash $85.8M
Debt $0.0M
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $61.0M | $75.1M | $92.9M | $83.0M | $85.8M |
| Debt incl. finance leases | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net debt / EBITDA | −3.1x | −3.7x | −5.3x | −5.8x | −7.0x |
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Current ratio | 19.5x | 15.1x | 22.6x | 25.6x | 37.6x |
| Quick ratio | 17.8x | 13.6x | 20.5x | 23.3x | 34.6x |
| Total assets | $116M | $124M | $135M | $123M | $123M |
| Total liabilities | $8.5M | $9.6M | $7.1M | $5.1M | $3.3M |
| Shareholders' equity | $107M | $114M | $128M | $117M | $119M |
| Net debt (− = net cash) | −$61.0M | −$75.1M | −$92.9M | −$83.0M | −$85.8M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Cash from operations is positive | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Return on assets rose | — | ✕ | ✓ | ✕ | ✕ | ✓ | ✓ | ✕ | ✕ | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✕ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Current ratio rose | — | ✕ | ✓ | ✓ | ✓ | ✓ | ✕ | ✓ | ✓ | ✓ |
| Share count didn't rise | — | ✓ | ✕ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Gross margin rose | — | ✓ | ✕ | ✓ | ✕ | ✓ | ✕ | ✕ | ✕ | ✕ |
| Revenue rose relative to assets | — | ✕ | ✕ | ✓ | ✕ | ✓ | ✕ | ✕ | ✕ | ✕ |
| F-score | — / 3 | 5 / 8 | 4 / 9 | 7 / 9 | 5 / 9 | 8 / 9 | 5 / 9 | 5 / 9 | 5 / 9 | 5 / 9 |
| Accruals ratio | −3.2% | −9.9% | 1.8% | −2.2% | −8.4% | −5.6% | −3.9% | −4.4% | −0.7% | −2.8% |
| Altman Z'' | 18.07 | 13.10 | 16.86 | 19.65 | 19.59 | 21.52 | 21.31 | 27.94 | 33.27 | 47.39 |
10 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $39.3M | $41.4M | $42.0M | $46.9M | $42.2M | $49.1M | $52.3M | $50.2M | $40.9M | $38.5M |
| Gross profit | $23.7M | $26.4M | $26.3M | $29.5M | $25.5M | $30.9M | $32.2M | $30.0M | $24.1M | $22.0M |
| Research and development | $0.5M | $0.4M | $0.5M | $0.5M | $0.5M | $0.5M | $0.5M | $0.6M | $0.8M | $0.7M |
| Operating income | $16.2M | $19.0M | $18.7M | $17.6M | $13.7M | $18.9M | $19.8M | $16.8M | $13.6M | $11.4M |
| Pretax income | $16.4M | $19.1M | $19.5M | $17.9M | $13.8M | $19.1M | $20.7M | $20.1M | $16.8M | $14.1M |
| Income tax | $4.3M | $10.6M | $0.9M | $3.2M | $3.0M | $4.3M | $4.2M | $3.5M | $2.9M | $2.8M |
| Net income | $12.1M | $8.5M | $18.6M | $14.7M | $10.8M | $14.8M | $16.5M | $16.6M | $13.9M | $11.3M |
| Diluted EPS | $3.22 | $2.28 | $4.95 | $3.94 | $2.94 | $4.04 | $4.52 | $4.57 | $3.96 | $3.48 |
| Diluted shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | $14.5M | $16.9M | $16.8M | $17.1M | $20.1M | $21.2M | $21.1M | $22.3M | $14.8M | $14.7M |
| Capital expenditure | $3.3M | $1.6M | $0.4M | $0.5M | $0.9M | $0.6M | $0.8M | $0.6M | $0.2M | $0.4M |
| Free cash flow | $11.2M | $15.3M | $16.4M | $16.5M | $19.3M | $20.7M | $20.3M | $21.6M | $14.6M | $14.3M |
| Depreciation and amortization | $0.6M | $0.7M | $0.8M | $0.7M | $0.7M | $0.6M | $0.6M | $0.6M | $0.7M | $0.8M |
| Stock-based compensation | $0.1M | $0.1M | $0.1M | $0.1M | $0.2M | $0.2M | $0.2M | $0.2M | $0.3M | $0.4M |
| Share buybacks | — | $0.0M | $1.2M | $0.4M | $7.0M | $0.0M | $2.5M | $0.0M | $20.0M | $8.4M |
| Dividends paid | $3.9M | $3.0M | $4.0M | $4.1M | $4.1M | $11.5M | $3.2M | $4.3M | $4.3M | $4.0M |
| Dividends and buybacks | $3.9M | $3.0M | $5.2M | $4.5M | $11.1M | $11.5M | $5.7M | $4.3M | $24.2M | $12.3M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $26.3M | $39.9M | $51.1M | $42.8M | $51.6M | $61.0M | $75.1M | $92.9M | $83.0M | $85.8M |
| Total debt | — | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Current assets | $34.5M | $49.2M | $60.9M | $54.9M | $62.3M | $73.2M | $89.9M | $106M | $96.3M | $97.7M |
| Current liabilities | $3.0M | $5.3M | $5.3M | $3.4M | $3.8M | $3.7M | $6.0M | $4.7M | $3.8M | $2.6M |
| Inventory | $4.5M | $5.2M | $6.9M | $6.9M | $6.2M | $6.6M | $8.8M | $9.6M | $8.8M | $7.9M |
| Property and equipment, net | $10.0M | $11.6M | $10.4M | $10.7M | $11.3M | $10.6M | $10.2M | $10.6M | $9.8M | $9.9M |
| Goodwill | $13.5M | $14.1M | $13.7M | $14.0M | $14.2M | $14.1M | $13.4M | $13.7M | $13.6M | $14.1M |
| Intangible assets | $18.3M | $17.8M | $14.8M | $30.2M | $24.0M | $17.8M | $10.4M | $4.9M | $2.9M | $0.8M |
| Total assets | $76.2M | $92.7M | $99.8M | $110M | $112M | $116M | $124M | $135M | $123M | $123M |
| Total liabilities | $6.9M | $14.6M | $10.8M | $8.7M | $8.9M | $8.5M | $9.6M | $7.1M | $5.1M | $3.3M |
| Preferred stock | — | $0.0M | $0.0M | $0.0M | — | — | — | — | — | — |
| Shareholders' equity | $69.2M | $78.1M | $89.0M | $101M | $103M | $107M | $114M | $128M | $117M | $119M |
| Margins | ||||||||||
| Gross margin | 60.3% | 63.7% | 62.6% | 62.8% | 60.6% | 63.0% | 61.6% | 59.8% | 59.0% | 57.1% |
| Operating margin | 41.2% | 45.9% | 44.5% | 37.6% | 32.5% | 38.5% | 37.9% | 33.4% | 33.2% | 29.6% |
| EBITDA margin | 42.7% | 47.5% | 46.3% | 39.1% | 34.1% | 39.8% | 39.0% | 34.6% | 35.0% | 31.7% |
| Net margin | 30.9% | 20.5% | 44.2% | 31.4% | 25.6% | 30.1% | 31.5% | 33.1% | 33.9% | 29.3% |
| FCF margin | 28.6% | 37.0% | 39.1% | 35.2% | 45.7% | 42.1% | 38.9% | 43.1% | 35.7% | 37.2% |
| Returns | ||||||||||
| Return on capital | — | 32.3% | 47.1% | 24.9% | 20.9% | 31.7% | 40.3% | 39.2% | 32.6% | 27.2% |
| Return on capital employed | 22.1% | 21.7% | 19.8% | 16.6% | 12.7% | 16.9% | 16.8% | 12.8% | 11.4% | 9.5% |
| Return on equity | 17.5% | 11.5% | 22.2% | 15.5% | 10.6% | 14.1% | 14.9% | 13.7% | 11.3% | 9.5% |
| Return on assets | 15.9% | 10.1% | 19.3% | 14.1% | 9.7% | 13.0% | 13.8% | 12.8% | 10.8% | 9.2% |
| Return on tangible equity | 32.3% | 18.4% | 30.7% | 25.9% | 16.7% | 19.6% | 18.2% | 15.2% | 13.7% | 10.8% |
| Growth | ||||||||||
| Revenue growth | — | 5.4% | 1.4% | 11.7% | −10.1% | 16.3% | 6.6% | −3.9% | −18.6% | −5.8% |
| Net income growth | — | −29.9% | 118.2% | −20.6% | −26.7% | 37.0% | 11.4% | 1.0% | −16.6% | −18.7% |
| EPS growth | — | −29.2% | 117.1% | −20.4% | −25.4% | 37.4% | 11.9% | 1.1% | −13.3% | −12.1% |
| FCF growth | — | 36.3% | 7.3% | 0.5% | 16.7% | 7.1% | −1.5% | 6.4% | −32.5% | −1.9% |
| Share count change | — | −0.8% | 0.3% | −0.2% | −1.8% | −0.3% | −0.5% | −0.2% | −3.7% | −7.5% |
| Financial health | ||||||||||
| Net debt / EBITDA | — | −2.0x | −2.6x | −2.3x | −3.6x | −3.1x | −3.7x | −5.3x | −5.8x | −7.0x |
| Debt / equity | — | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Current ratio | 11.4x | 9.3x | 11.6x | 15.9x | 16.4x | 19.5x | 15.1x | 22.6x | 25.6x | 37.6x |
| Quick ratio | 9.9x | 8.3x | 10.3x | 13.9x | 14.8x | 17.8x | 13.6x | 20.5x | 23.3x | 34.6x |
| Capital allocation | ||||||||||
| Capex / revenue | 8.4% | 3.9% | 1.0% | 1.2% | 2.0% | 1.1% | 1.5% | 1.3% | 0.6% | 1.0% |
| Stock comp / revenue | 0.2% | 0.3% | 0.2% | 0.2% | 0.4% | 0.3% | 0.4% | 0.4% | 0.6% | 1.0% |
| Payouts / FCF | 34.9% | 19.3% | 31.8% | 27.3% | 57.5% | 55.5% | 27.8% | 19.8% | 165.9% | 86.2% |
| Quality scores | ||||||||||
| Piotroski F-score | — | 5.0 | 4.0 | 7.0 | 5.0 | 8.0 | 5.0 | 5.0 | 5.0 | 5.0 |
| Altman Z'' | 18.1 | 13.1 | 16.9 | 19.7 | 19.6 | 21.5 | 21.3 | 27.9 | 33.3 | 47.4 |
| Accruals ratio | −3.2% | −9.9% | 1.8% | −2.2% | −8.4% | −5.6% | −3.9% | −4.4% | −0.7% | −2.8% |
Source: SEC EDGAR XBRL filings (CIK 0000706698). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.